NEWS & EVENTS

Catalent today announced a collaboration with Johnson & Johnson for large-scale commercial manufacturing at its facility in Bloomington, Indiana of Johnson & Johnson’s lead vaccine candidate for COVID-19.

Catalent today announced that two of its experts will present at upcoming virtual industry conferences: CPhI North America Webinar Week; and Clinical Trial Supply 2020 – A Virtual Experience.

Catalent today announced the completion of its $14 million expansion to increase the biologics packaging capabilities and capacity at its Bloomington, Indiana facility.

Catalent today published its first Corporate Responsibility (CR) Report, covering fiscal year 2019. The report brings a new level transparency and ambition to a wide range of ESG topics related to Catalent’s business.

Catalent today announced that it has been recognized by the Royal Society for the Prevention of Accidents for its health and safety practices, achieving a silver award for a second consecutive year.

Catalent today welcomed the announcement by Biohaven Pharmaceutical, that the U.S. Food and Drug Administration has approved its NURTEC™ ODT (rimegepant) for the acute treatment of migraine in adults.

Catalent welcomes the announcement by Blueprint Medicines Corporation that the FDA has approved AYVAKIT™ for the treatment of adults with unresectable or metastatic GIST harboring a PDGFRA exon 18 mutation.

Perrigo and Catalent today announced that the FDA has approved Perrigo’s abbreviated new drug application for generic albuterol sulfate inhalation aerosol, the first AB-rated generic version of ProAir® HFA

Catalent today announced that Senior Vice President & Chief Financial Officer, Wetteny Joseph, has been inducted as a member of the Executive Leadership Council (ELC).